WX390 not checked
Shanghai Jiatan Pharmatech Co., Ltd · WXFL10030390
FollowEvery change as it happens, and a Monday email
What this is
- How it works
- How it works isn't classified yet
- How it’s given
- “Participants will receive WX390 continuous oral dosing (1.1 mg once a day) and Toripalimab fixed dose (240mg, intravenous, Day 1, every 3 weeks).”In the company’s words, NCT07392060 on ClinicalTrials.gov
- Tested for
- Cervical Cancer Metastatic, Gastric Type Adenocarcinoma (GAS) With STK11 Mutation, Solid Tumor
- Main trialPhase 3
- “This is a Randomized, Open-Label, Controlled, Multicenter Phase III Clinical Study to evaluate the efficacy of WX390 in combination with toripalimab versus investigator's choice of therapy in patients with recurrent or metastatic cervical cancer who have failed at least one prior platinum-based systemic therapy, as assessed by overall survival (OS).”In the company’s words, NCT07392060 on ClinicalTrials.gov
- Other names
- WXFL10030390
Other drugs for Solid Tumor
- AvelumabEMD Serono Research & Development Institute, Inc. · Phase 3
- AlectinibRoche · Phase 3
- AtezolizumabRoche · Phase 3
- AU-011Aura Biosciences · Phase 3
- BevacizumabRoche · Phase 3
- CadonilimabAkeso · Phase 3
Coming up1
- 30 Sep 2029Phase 3 trial completes · ClinicalTrials.gov
Changes0
Last 90 daysNo changes yet. We started recording changes on 6 Nov 2026.
Trials6
| Trial | Phase | Completes | What it tests |
|---|---|---|---|
| Phase 3Not yet recruiting | 30 Sep 2029 | A Phase III Clinical Study of WX390 Combined With Toripalimab Versus Investigator's Choice of Therapy in Patients With Recurrent or Metastatic Cervical Cancer Who Have Failed Prior Platinum-Based Treatment | |
| Phase 2Recruiting | 12 Dec 2025 | A Study of WX390 Combined With Toripalimab in Patients With Advanced Gastric-type Endocervical Adenocarcinoma With STK11 Mutations | |
| Phase 1/2Recruiting | 9 Nov 2025 | A Study of WX390 Combined With Toripalimab in Patients With Advanced Solid Tumors | |
| Phase 2Unknown | 12 Jun 2025 | A Study of WX390 in Patients With Advanced Solid Tumors | |
| Phase 1/2Completed | 3 Jan 2023 | A Study of WX390 in Patients With Advanced Solid Tumors With PIK3CA Mutations | |
| Phase 1Completed | 25 Jul 2020 | A Study of WXFL10030390 in Patients With Advanced Solid Tumors or Lymphoma |
A trial in both registries shows both numbers.
About
- Sources
- ClinicalTrials.gov updated 18 Nov 2026 · EU trials register (CTIS) updated 18 Nov 2026 · openFDA updated 17 Nov 2026